TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB

摘要

Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody ("mAh") or the antigen-binding fragment of a mAh against human vascular endothelial growth factor ("hVEGF") - such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment - to the retina/vitreal humour in the eye(s) of human subjects diagnosed with diabetic retinopathy.